Gaithersburg, Maryland-based biotechnology company Novavax Inc. (NASDAQ:NVAX), currently valued at approximately $1 billion in market capitalization, has disclosed a recent communication from the U.S. Food and Drug Administration (FDA) requesting additional clinical data as part of a post-marketing commitment (PMC). According to InvestingPro data, the company faces challenging market conditions with a significant 30.7% revenue decline in the last twelve months. This request came after Novavax’s ongoing discussions with the FDA concerning the approvability of their Biologics License Application (BLA).
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,